ADVERTISEMENT

Financing

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs

Public Company Edition: Upstream grossed $255m and CAMP4 raised $75m in October’s first initial public offerings. In follow-on offerings, Crinetics and Scholar Rock brought in $500m and $300m, respectively. Also, Turnstone cut 60% of its workforce and Gritstone filed for bankruptcy.

VC Funding Dips In Q3, But 2024 Already Bests Full-Year 2023

VC Funding Dips In Q3, But 2024 Already Bests Full-Year 2023

Data from Evaluate show that biopharma venture capital investment fell from $7.95bn in Q2 to $6.59bn in Q3, but both outpaced every quarter in 2023 as the financial market recovery continues.

Q3 Korean Biotech Roundup: Eyes On Orum's IPO Plan

Q3 Korean Biotech Roundup: Eyes On Orum's IPO Plan

Recent major developments in the Korean biotech sector include Orum Therapeutics’ IPO plan and HLB’s US resubmission for the approval of rivoceranib in combination with camrelizumab for first-line liver cancer.

Marabio Systems Raised $19M In Series A For Blood Test To Detect Autism

Marabio Systems Raised $19M In Series A For Blood Test To Detect Autism

Marabio Systems says the new funding will help accelerate efforts to bring a blood test to market in 2025 that will accurately determine if a mother is a carrier of antibodies that cause MARA, a subtype of autism that believe to cause more severe behavior.

Quarterly IPOs Climb Back Above $1bn

Quarterly IPOs Climb Back Above $1bn

But biotechs are still having to price their offerings lower than they had planned.    

BioBytes: AI-Related Deals in Q3 2024

BioBytes: AI-Related Deals in Q3 2024

The big news in Q3 2024 was the acquisition of Exscientia by Recursion, which has now expanded its pipeline and gained access to more contracts, but this quarter was also marked by numerous seed rounds and M&As, with the strengthening of existing companies and emergence of new ones into what is becoming a crowded space.  

Moderately Optimistic: Rounding Out Deal Making In 2024

Moderately Optimistic: Rounding Out Deal Making In 2024

Dealmaking trends in 2024 point toward a healthier financial ecosystem than in 2023. However, with a challenging three quarters in 2024, enthusiasm should be curbed as 2024 rounds out in a slow and steady manner.

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

We Built This City: Maraganore’s Latest Start-Up Aims For Smaller RNAi Drugs

We Built This City: Maraganore’s Latest Start-Up Aims For Smaller RNAi Drugs

Emerging from ARCH, City Therapeutics has launched with $135m in series A funding and the Alnylam founder as its executive chairman.

Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney

Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney

Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.